Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

Clinical research tech firm Advarra has unveiled a new digital solution meant to help speed up study starts and facilitate ...

Among his first actions as president, Donald Trump has rescinded an executive order signed during the Biden administration ...

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. | Tris Pharma has pointed to a phase 3 win for its pain ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to ...

Disc Medicine has finalized the design of the confirmatory trial for its rare blood disorder drug candidate, adding a ...

Inflammatix has secured the FDA’s blessing for its in vitro diagnostic system, aimed at rapidly profiling the body’s response ...